PURPOSE In the randomized open-label phase III OVHIPEC trial, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved recurrence-free and overall survival in patients with stage III ovarian cancer. We studied the cost effectiveness of the addition of HIPEC to interval CRS in patients with ovarian cancer. PATIENTS AND METHODS We constructed

BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has improved the survival in selected colorectal cancer patients with peritoneal metastases. In these patients, the risk of a low anastomosis is sometimes diminished through the creation of a colostomy. Currently, the morbidity and mortality associated with the reversal of the colostomy in this population

PURPOSE: Primary cytoreductive surgery (CRS) and peri-operative intraperitoneal chemotherapy (PIC) is the only curative option for patients with colorectal cancer peritoneal carcinomatosis (PC). A significant proportion of patients develop peritoneal recurrence. Outcomes of patients undergoing secondary CRS and PIC for recurrent PC were examined.METHODS: All patients undergoing second procedures w

Hybridization allows adaptations to be shared among lineages and may trigger the evolution of new species1,2. However, convincing examples of homoploid hybrid speciation remain rare because it is challenging to demonstrate that hybridization was crucial in generating reproductive isolation3. Here we combine population genomic analysis with quantitative trait locus mapping of species-specific trait

Kursen Arbetsorganisation och ledarskap avslutades med en konferens där studenterna presenterade sina projektarbeten. Dessa arbeten är sammanställda i artiklar med olika teman kopplat till dagens arbetsliv. Årets konferens speglar aktuella frågor och utmaningar i näringslivet såsom ökad automation, företags sociala ansvar (CSR), konflikthantering, framgångsfaktorer för nya projektledare, modernt l

We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to Inte

Studies of fully-reconstructed jets in heavy-ion collisions aim at extracting thermodynamical and transport properties of hot and dense QCD matter. Recently, a plethora of new jet substructure observables have been theoretically and experimentally developed that provide novel precise insights on the modifications of the parton radiation pattern induced by a QCD medium. This report, summarizing the

BACKGROUND: The OVHIPEC-1 trial previously showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved progression-free and overall survival compared with cytoreductive surgery alone at 4·7 years of follow-up in patients with stage III epithelial ovarian cancer who were ineligible for primary cytoreduction. We report the fina

Background and Clonal haematopoiesis of indeterminate potential (CHIP), the age-related expansion of blood cells with preleukemic mutaAims tions, is associated with atherosclerotic cardiovascular disease and heart failure. This study aimed to test the association of CHIP with new-onset arrhythmias.Methods UK Biobank participants without prevalent arrhythmias were included. Co-primary study outcome

Aims Delcasertib is a selective inhibitor of delta-protein kinase C (delta-PKC), which reduced infarct size during ischaemia/reperfusion in animal models and diminished myocardial necrosis and improved reperfusion in a pilot study during primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI). Methods and results A multicentre, double-blind trial was perform

The Prize for Future Innovations is awarded by Lund University and Sparbanken Skåne. Since the start in 2017 we have seen hundreds of exciting, innovative, and sometimes downright weird ideas. Every year, the prize jury has the pleasant but difficult job of selecting the winners. So here they are, the winners of Lund University and Sparbanken Skåne’s Future Innovations Prize.  2023 Category Employ

https://www.innovation.lu.se/en/futureinnovations/previous-prize-winners - 2025-08-29

Researcher Contact details Email: jayne [dot] svenungsson [at] ctr [dot] lu [dot] se Phone: +46 46 222 43 39Organisation Systematic Theology Room number: LUX:B327 WebpageJayne Svenungssons profile in Lund University research portalOther affiliations Researcher MECW: The Middle East in the Contemporary World Researcher Centre for Advanced Middle Eastern Studies (CMES) Principal investigator Christi

https://www.cmes.lu.se/jayne-svenungsson - 2025-08-29

Therese Bülow Jørgensen The Gaze of a Player: Better Smize while Entering the Woods, 2020 Video installation. 14 min. loop They didn’t even remember how they got here. The feeling of having been put on pause was there when they woke up, but that cannot be true, can it? This is another space. It’s a gateway, an ornament made out of wool, moist, light wear and pine forest. It is a documentation of a

https://www.khm.lu.se/en/sites/khm.lu.se.en/files/text_bfa3.pdf - 2025-08-30

Priset för Framtidens innovationer har delats ut tillsammans med Sparbanken Skåne sedan 2017, och vi har sett hundratals spännande, nytänkande – och ibland helt tokiga – idéer. Vår jury har varje år haft ett angenämt men stundtals svettigt jobb att sålla ut vinnarna. Men här är de, våra pristagare i Lunds universitets och Sparbanken Skånes Pris för Framtidens innovationer.  Vinnare 2023, Paula Run

https://www.innovation.lu.se/framtidensinnovationer/tidigare-pristagare - 2025-08-29

Prefekt Kontaktinformation E-post: anna [dot] lundberg [at] soclaw [dot] lu [dot] se Mobil: +46 70 946 62 30Organisation Rättssociologiska institutionen Hämtställe: 31 WebbplatsAnna Lundbergs profil i Lunds universitets forskningsportalAndra roller Professor Rättssociologiska institutionen Profilområdesmedlem LU profilområde: Mänskliga rättigheterForskningsområdenKollektiv rättsmobiliseringLokalt

https://www.soclaw.lu.se/anna-lundberg - 2025-08-29

Senior Professor Kontaktinformation E-post: diana [dot] mulinari [at] genus [dot] lu [dot] se Telefon: +46 46 222 97 04Organisation Genusvetenskap Hämtställe: 31 WebbplatsDiana Mulinaris profil i Lunds universitets forskningsportalAndra roller Forskare GenusvetenskapBakgrund:Jag disputerade i sociologi vid Lunds Universitet 1996 med avhandling Motherwork in Revolutionary Nicaragua. Docent i sociol

https://www.genus.lu.se/diana-mulinari - 2025-08-29

ODEUM PRESENTERAR LUNDS UNIVERSITETS MUSIKCENTRUM | PROGRAMBOK HÖSTEN 2020 Välkomna till Odeums evenemang under hösten! Efter en pandemisk vårtermin, då alltför många konserter fick ställas in, ser vi nu fram emot en händelserik höst med många spännande evenemang. Under hösten fortsätter Odeum sin satsning på tematiserade evenemangsserier där turen nu kommit till 250-årsfirande Ludwig van Beethove

https://www.odeum.lu.se/en/sites/odeum.lu.se.en/files/odeum_program_host_2020.pdf - 2025-08-30

1 List of publications – Charlotte Ling (690420-4986) 1 LIST OF PUBLICATIONS – CHARLOTTE LING Total of 103 original publications, 18 invited review papers and 8 book chapters since 1999 H-index: 42; Number of citations ~8.500 Original publications 1. Madhusudhan Bysani, Rasmus Agren, Cajsa Davegårdh, Petr Volkov, Tina Rönn, Per Unneberg, Karl Bacos and Charlotte Ling ATAC-seq reveals alterations i

https://www.ludc.lu.se/sites/ludc.lu.se/files/list_of_publications_c_ling_maj_2019.pdf - 2025-08-30

The 9th biennial conference titled “Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases” was hosted virtually, due to the ongoing COVID-19 pandemic, in collaboration with the University of Vermont Larner College of Medicine, the National Heart, Lung, and Blood Institute, the Alpha-1 Foundation, the Cystic Fibrosis Foundation, and the International Society for Cell & Gen

BACKGROUND: Intraperitoneal chemotherapy has an established role in the treatment of selected patients with colorectal peritoneal metastases. Oxaliplatin is highly suitable as a chemotherapeutic agent for hyperthermic intraperitoneal chemotherapy (HIPEC), but its use to date has been limited because of the morbidity caused by severe electrolyte and glycemic imbalances associated with 5% glucose as